Showing results (191-200 of 419) with videos related to
Sort By:
Pageof 42
Healthcare (Basel, Switzerland)|December 17, 2024
Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer CentersDenis Horgan, Marc Van den Bulcke, Núria Malats, et al.CA: a Cancer Journal for Clinicians|January 4, 2024
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidanceRaffaella Casolino, Philip A Beer, Debyani Chakravarty, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
Real-World Biomarker-Associated Therapy in Metastatic Carcinoma of Unknown Primary: Prevalence, Impact, and OutcomesDipesh Uprety, Kieran Sweeney, Lubina Arjyal, et al.Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.Journal of Medicinal Chemistry|December 26, 2024
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the ProteinYafeng Wang, Xueqing Hu, Shriya Pandey, et al.Cancer Chemotherapy and Pharmacology|September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvementElena Fountzilas, Elangovan Krishnan, Filip Janku, et al.British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.The Oncologist|September 15, 2021
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 TrialAnna Minchom, Aaron C Tan, Erminia Massarelli, et al.Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.Pageof 42